Inside Therapeutics partners with Meiwafosis Co., Ltd. to bring microfluidic nanoparticle formulation technology to scientists in the country, backed by a distributor who knows the local research landscape inside and out.
Following growing acceptance in Europe, driven by theoretical labs and biotech organizations, with installations at renowned institutions, TAMARA endures its international rollout.
Since 1968, Meiwafosis has been connecting Japanese universities, research institutions, and organizations with the significant scientific devices the world has to offer. Five locations, decades of technical expertise, and a reputation built on sincerely understanding what researchers required: a significant foundation to bring TAMARA to Japan.
Scientists will recently have local access to TAMARA, with demos, training, and technical help available directly in Japan. In practice, this means rapid support and fewer delays for teams working on RNA-LNPs, liposomes, peptide nanoparticles, or other nanoparticle-driven delivery technology, from early screening (200 µL) via preclinical development, all in the same technology.
"Our partnership with Inside Therapeutics reflects our long-standing commitment to advancing scientific research in Japan. TAMARA is exactly the kind of innovation we're proud to introduce to our network, a solution that will help accelerate nanoparticles and RNA-based research across the country."
This collaboration builds on TAMARA's growing footprint in Europe, and Japan is a natural next step, a research ecosystem which shift rapidly and demands tools that keep up.
According to Towards Healthcare, the microfluidic lipid nanoparticle manufacturing market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 149.16 million in 2026 to approximately USD 1465.34 million by 2035, representing a compound annual growth rate (CAGR) of 28.9% from 2026 to 2035, driven by microfluidics, which allows excellent control over LNP size distribution and polydispersity index (PDI).
This exactness is significant for optimizing pharmacokinetics and cellular uptake, directly impacting therapeutic effectiveness. Microfluidic platforms drive rapid screening of preparation parameters, hastening the development cycle of novel LNP-driven therapeutics. Major microfluidic technology provides seamless scalability from preclinical to industrial manufacturing volumes, maintaining consistent physicochemical characteristics across the large scales.
LNPs are significantly evolving as significant vectors in mRNA-based cancer management. By effectively delivering mRNA encoding tumor antigens, cytokines, and therapeutic proteins, these nanoparticles are improving immune responses against cancer cells. This technology is creating advanced opportunities in cancer vaccine development and modified immunotherapies, making it a highly efficient area of research and clinical trials.
Microfluidic production of LNPs allows rapid and scalable creation of targeted formulations. This enables tailoring management to individual patient profiles based on genetic markers or particular disease properties, specifically beneficial in oncology and rare genetic disorders.
The TAMARA platform is a standard for R&D versatility, capable of synthesizing a variety of polymer and lipid-driven nanoparticles, including RNA LNPs, liposomes, solid lipid nanoparticles (SLNs), polymeric nanoparticles, and advanced next-generation nanoparticles.
Inside Therapeutics is a French Deeptech Bio organization to streamline nanomedicine manufacturing, from each drug discovery step, all via clinical steps, and up to large pharma manufacturing. Inside Therapeutics provides microfluidic-based technology for nanoparticle manufacturing, focusing on LNP-RNA vaccine advancement and oncology. Inside Therapeutics transforms nanoparticle manufacturing with intuitive platforms intended to speed up and scale up LNP-RNA vaccine advancement. The company provides innovative microfluidic-based technology, like the TAMARA Nanoparticle Formulation System, which enhances RNA therapy manufacturing by lowering time and expenses associated with formula adaptations. Inside Therapeutics focuses on therapeutic applications, specifically in oncology, and offers solutions for the synthesis of different nanoparticle types, including liposomes, LNP-xRNA, SLN, and PLGA.
A recent report by Towards Healthcare highlights that the microfluidic lipid nanoparticle manufacturing market is witnessing growth because microfluidics offers significant advantages for RNA-based LNP production, involving precise LNP size controllability, high reproducibility, high-throughput optimization of LNP formulation, and nonstop LNP-production processes. Microfluidic platforms have superior control over particle size and spreading. By precisely modifiable flow rates and channel geometry, very uniform nanoparticles with low polydispersity were produced for dependable drug delivery.
